Nyrada said its PCSK9 inhibitor (NYX-PCSK9i) showed an increase in LDL receptor levels akin to Amgen's PBS-listed REPATHA (evolocumab) and Sanofi's recommended but not yet listed PRALUENT (alirocumab). …
Latest Video
New Stories
-
AusBiotech appoints experienced Sanofi leader as its new chief executive
April 23, 2024 - - Latest News -
Should principles such as 'equity' and 'opportunity cost' be applied consistently or not at all?
April 23, 2024 - - Latest News -
Rare Cancers Australia welcomes new appointments to its board of directors
April 23, 2024 - - Latest News -
BMS and Australian venture capital firm back immunotherapy company Pathios Therapeutics
April 23, 2024 - - Latest News -
NZ patients campaigning against Pharmac's decision to force a switch on insulin pumps
April 23, 2024 - - Latest News -
Tour de Cure backs further development of Noxopharm's preclinical brain cancer candidate
April 22, 2024 - - Australian Biotech -
Mark Butler announces NHMRC funding for six telehealth research projects
April 22, 2024 - - Latest News